Recently, the results of various large CV outcome trials (CVOTs) [10] in patients with T2D at high CV risk treated with novel glucose lowering agents, such as Dipeptidyl peptidase 4 inhibitors (DPP4-I), sodium–glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), substantially expanded available therapeutic options, leading to numerous evidence-based recommendations for the management of this patient population [2,10]. This evidence concerns the gene GCG and type 2 diabetes mellitus.